Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 10-17

  Brady, Kathleen A ^a,c   Boston, Ray C ^b   Aldrich, Jennifer L ^a   MacGregor, Rob Roy ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Cerebrospinal fluid; Human immunodeficiency virus; Pharmacokinetics; Stavudine

Indexed keywords

STAVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; DIET RESTRICTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LUMBAR PUNCTURE; LYMPHOCYTE COUNT; MALE; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE; HIV INFECTIONS; HUMANS; LEUKOCYTE COUNT; MALE; PROTEINS; STAVUDINE; TIME FACTORS;

EID: 11144225605     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.10.55625     Document Type: Article

References (26)

1. 3. J Acquir Immune Defic Syndr 1999;22:39-48.
2. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial, Bristol-Myers Squibb stavudine/019 study group. Ann Intern Med 1997;126:355-63.
3. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992;166:480-5.
4. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995;39:2309-15.
5. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 1997;33:276-84.
6. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Human Retroviruses 2003;19:825-35.
7. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome: HIV neurobehavioral research center group [comments]. Ann Neurol 1997;42:679-88.
8. Goudsmit J, de Wolf F, Paul D, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986;2:177-80.
9. Davis L, Hjelle B, Miller V, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992;42:1736-9.
10. Royal WR, Seines O, Concha M, Nance-Sproson T, McArthur J. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia. Ann Neurol 1994;36:32-9.
11. Singer E, Syndulko K, Fahy-Chandon B, et al. Cerebrospinal fluid p24 antigen levels and intrathecal immunoglobulin G synthesis are associated with cognitive disease severity in HIV-1. AIDS 1994;8:197-204.
12. Geleziunas R, Schipper H, Wainberg M. Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS 1992;6:1411-26.
13. Morse G, Lechner J, Santora J, Rozek S. Zidovudine update: 1990. Drug Intell Clin Pharm 1990;24:754-60.
14. Foudraine NA, Hoetelmans RM, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-51.
15. Haworth SJ, Christofalo B, Anderson RD, Dunkle LM. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquired Immune Defic Syndr Human Retrovirol 1998;17:235-8.
16. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995;171(suppl 2):S99-112.
17. Janiszewski J, Mulvana D, Kaul S, Dandekar K, Barbhaiya R. High-performance liquid chromatographic determination of 2′,3′- didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J Chromatogr 1992;577:151-6.
18. Greif P, Wastney M, Linares O, Boston R. Balancing needs, efficiency, and functionality in the provision of modeling software: A perspective of the NIH WinSAAM project. In: Clifford A, Mueller H, eds. Mathematical modeling in experimental nutrition, vol 445. New York: Plenum, 1998: 3-20.
19. Stefanovski D, Moate PJ, Boston RC. WinSAAM: a windows-based compartmental modeling system. Metab Clin Exp 2003;52:1153-66.
20. Herndon R, Brumback R. The cerebrospinal fluid. Boston: Kluwer Academic Publishers, 1989.
21. Fishman R. Cerebrospinal fluid in diseases of the nervous system, 2nd ed. Philadelphia: WB Saunders, 1992.
22. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996;51:846-64.
23. Lin PF, Gonzalez CJ, Griffith B, et al. Stavudine resistance: an update on susceptibility following prolonged therapy. Antiviral Ther 1999;4:21-8.
24. Foudraine NA, De Jong JJ, Van Benthem B, et al. A randomized controlled trial to compare AZT/3TC vs d4T/3TC with a response-dependent addition of indinavir in ART-naive patients with HIV [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:377.
25. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96(2 pt 1):247-52.
26. Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Human Retroviruses 2000;16:1491-502.